Recent Price Movement and Market Context
On 27 Jan 2026, Mankind Pharma Ltd’s stock touched an intraday low of Rs.2060, representing a 2.03% decline on the day and a 0.63% drop compared to the previous close. This marks the lowest price level for the stock in the past 52 weeks, down from its high of Rs.2726.75. The stock has been on a downward trajectory for two consecutive sessions, losing 2.58% over this period. It has also underperformed the Pharmaceuticals & Biotechnology sector by 0.88% today.
The broader market environment has been challenging, with the Sensex opening 100.91 points lower and trading at 81,393.52, down 0.18%. The Sensex itself has experienced a three-week consecutive decline, losing 2.61% in that timeframe. Notably, other indices such as NIFTY MEDIA and NIFTY REALTY also hit new 52-week lows today, indicating sector-wide pressures.
Mankind Pharma’s share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bearish trend. The Sensex, while trading below its 50-day moving average, still maintains a 50DMA above its 200DMA, suggesting some underlying market resilience despite recent weakness.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Financial Performance and Valuation Metrics
Mankind Pharma’s recent financial results have contributed to the subdued market sentiment. The company reported flat results in the September 2025 quarter, with profit after tax (PAT) for the latest six months at Rs.949.83 crores, reflecting a decline of 20.05% compared to the previous period. Interest expenses for the nine months stood at Rs.530.87 crores, marking a significant increase of 122.24%, which has weighed on profitability.
The company’s return on capital employed (ROCE) for the half year was recorded at 12.33%, one of the lowest levels in recent years. This contrasts with a higher management efficiency figure, where ROCE was noted at 25.78%, indicating some disparity in capital utilisation metrics. Despite this, the overall ROCE of 11.7% combined with an enterprise value to capital employed ratio of 4.5 suggests that the stock is trading at a premium relative to its historical and peer valuations.
Over the past year, Mankind Pharma’s stock has generated a negative return of 15.13%, underperforming the Sensex, which gained 7.98% over the same period. Profitability has also declined by 17.2% year-on-year, highlighting challenges in maintaining earnings growth. The stock’s performance has been below par not only in the near term but also over longer horizons, underperforming the BSE500 index across one-year, three-year, and three-month intervals.
Balance Sheet and Institutional Holding Insights
On the balance sheet front, Mankind Pharma demonstrates a strong ability to service its debt, with a low debt to EBITDA ratio of 0.54 times. This indicates manageable leverage levels and a relatively stable financial position. Institutional investors hold a significant 24.59% stake in the company, reflecting confidence from entities with extensive resources and analytical capabilities.
Despite the stock’s recent decline, the company’s management efficiency remains a positive aspect, as reflected in the higher ROCE figure of 25.78%. This suggests that while overall returns have softened, the company’s core operational management retains effectiveness in capital utilisation.
Mankind Pharma Ltd or something better? Our SwitchER feature analyzes this large-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Comparative Sector and Market Performance
Within the Pharmaceuticals & Biotechnology sector, Mankind Pharma’s valuation and price performance have lagged behind peers. The stock’s premium valuation multiples, combined with declining profitability and subdued returns, have contributed to its relative underperformance. The sector itself has faced headwinds, with several indices hitting 52-week lows, reflecting broader market pressures and sector-specific dynamics.
The Sensex’s recent three-week decline of 2.61% and its trading below the 50-day moving average further contextualise the challenging environment in which Mankind Pharma’s shares have fallen. While the Sensex maintains some technical support with its 50DMA above the 200DMA, the current trend indicates cautious market sentiment.
Summary of Key Metrics
To summarise, Mankind Pharma Ltd’s stock has reached a 52-week low of Rs.2060 amid a combination of flat recent results, increased interest expenses, declining profits, and premium valuation multiples. The stock’s underperformance relative to the Sensex and its sector, alongside trading below all major moving averages, underscores the current market challenges faced by the company.
Financial indicators such as a low ROCE of 12.33% for the half year and a debt to EBITDA ratio of 0.54 times provide a mixed picture of operational efficiency and financial stability. Institutional holdings remain relatively high at 24.59%, reflecting continued interest from sophisticated investors despite the recent price weakness.
Overall, the stock’s recent price action and fundamental metrics highlight a period of subdued performance within a broader market context that has seen multiple indices reach new lows.
Unlock special upgrade rates for a limited period. Start Saving Now →
